













# LEO Pharma pipeline overview

## 2023, Q2

Project*	Description	Partners	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration
<b>Delgocitinib</b> LP0133	A pan-JAK inhibitor under development for topical use in patients with chronic hand eczema and / or frontal fibrosing alopecia.						
<b>Anti IL-22R</b> LP0145	An IL-22 receptor antagonist under development for use in patients with atopic dermatitis.						
<b>Izuforant</b> LP0190	A histamine 4 receptor (H4R) antagonist under development for use in patients with atopic dermatitis.						
<b>Anti IgE<sup>+</sup>B-cell</b> LP0201	A monoclonal antibody for use in patients with allergic asthma.						
<b>LEO 158968</b> LP0189	A monoclonal antibody under development for the treatment of anti-inflammatory skin diseases.						
<b>IL-17 PPI<sub>m</sub></b> LP0128	An IL-17 PPI modulator						

\*Project compounds in our pipeline are investigational only and have not been approved by any regulatory authority.

 Finalized phase  
 Current phase

